Patients should be advised to: Start with the lowest dose and increase slowly Eat smaller, more frequent meals Avoid high-fat foods Stay well-hydrated Safety monitoring should include vigilance for: Pancreatitis symptoms (severe persistent abdominal pain) discontinue immediately if suspected Gallbladder disease increased risk with rapid weight loss Hypoglycaemia particularly when combined with insulin or sulphonylureas Renal function deterioration especially with dehydration from gastrointestinal effects Diabetic retinopathy monitor in patients with pre-existing retinopathy, particularly with semaglutide Suspected adverse reactions should be reported via the MHRA Yellow Card scheme
10.1016/j.brainresbull.2017.05.008 Brain Res
This potentially illustrates how sex-based differences in the use of GLP-1 medications may influence uveitis risk, highlighting the importance of needing to better approach adults with diabetes regarding eye health, the researchers highlighted in their abstract
Nevi with concerning histopathological features are common when sampled from special sites, such as the scalp or genitalia
If you see yourself in what I described and you are interested in starting a personalized nutrition program focused on well-being, you can send me a private message to book a free introductory video consultation and begin your path
The NIHR 'Be Part of Research' portal (bepartofresearch.nihr.ac.uk) provides information on trials recruiting in the UK and can help identify whether any retatrutide studies are open to participants
